Nurse Practitioner Josie Montegaard will present on the basics of CLL, including its biology, the distinction between CLL and SLL, its classification as a chronic disease, symptoms and how it presents, diagnosis and testing, as well as potential causes, including genetic and environmental factors.
In his book, Dr. Nabhan acknowledges the invaluable role care partners play for their loved ones living with CLL and the toll doing so can have.
Blocking the BTK pathway transformed treatment for CLL, but resistance can develop. The BTK degrader destroys it with two-thirds of patients responding.
Combining the new BCL2 inhibitor sonrotoclax with the BTK inhibitor zanubrutinib produced an overall response rate of 97% in relapsed CLL / SLL.
The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.
People with CLL and SLL are at higher risk of developing infections due to having weakened immune systems.
Receiving a cancer diagnosis is a challenging and emotional experience that can trigger a range of emotions including sadness, anxiousness, & worry.
CAR-T therapy is a potent cellular immune treatment that genetically trains an individual’s immune system to both recognize and attack cancerous cells.
It is critical to be aware of the signs and symptoms that may indicate there is a need to begin treatment.
